Facebook
Twitter
Telegram
Report an ErrorCelldex Therapeutics Cash Flow 2011-2024 | CLDX
Annual Cash Flow Celldex Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-107 M | -104 M | -60.9 M | -40.4 M | -46.4 M | -75.2 M | -99.9 M | -113 M | -98.9 M | - | - | - | - |
Depreciation & Amortization |
3.01 M | 2.9 M | 3.07 M | 3.93 M | 4.86 M | 3.58 M | 4.41 M | 3.1 M | 3 M | 2.39 M | 1.93 M | 2.05 M | 2.25 M |
Accounts Payables |
3.49 M | 3.34 M | 1.23 M | 1.05 M | 1.17 M | 1.07 M | 1.72 M | 1.74 M | 1.51 M | 2.6 M | 2.24 M | 745 K | 935 K |
Accounts Receivables |
2.63 M | 347 K | 172 K | 1.8 M | 1.02 M | 3.16 M | 1.88 M | 1.78 M | 970 K | 427 K | 489 K | 44 K | 170 K |
Total Inventories |
- | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Celldex Therapeutics
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-40.6 M | - | - | - | -28.6 M | - | -82 M | -46.8 M | -24.5 M | - | -46.4 M | -30 M | -18.1 M | - | -35.2 M | -23.3 M | -12.1 M | - | -35.4 M | -24.3 M | -13.2 M | - | -59.8 M | -45.4 M | -28 M | - | -80.4 M | -56 M | -35.3 M | - | -92.7 M | -68.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
775 K | - | - | - | 726 K | - | 2.22 M | 1.55 M | 811 K | - | 2.29 M | 1.54 M | 775 K | - | 3.17 M | 2.31 M | 1.16 M | - | 3.71 M | 2.5 M | 1.35 M | - | 2.86 M | - | 1.03 M | - | 3.39 M | 2.37 M | 1.37 M | - | 2.14 M | 1.43 M | 742 K | - | 2.15 M | 1.38 M | 672 K | - | 1.76 M | 1.16 M | 579 K | - | 1.42 M | 943 K | 468 K | - | 1.58 M | 1.07 M | 544 K | - | 1.7 M | 1.13 M | 562 K |
Accounts Payables |
3.23 M | 3.49 M | 3.59 M | 881 K | 3.37 M | 3.34 M | 2.27 M | 902 K | 1.02 M | 1.23 M | 836 K | 685 K | 997 K | 1.05 M | 1.05 M | 1.05 M | 1.05 M | 1.17 M | 1.17 M | 1.17 M | 1.17 M | 1.07 M | 1.07 M | 1.07 M | 1.07 M | 1.72 M | 1.72 M | 1.72 M | 1.72 M | 1.74 M | 1.74 M | 1.74 M | 1.74 M | 1.51 M | 1.51 M | 1.51 M | 1.51 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.24 M | 2.24 M | 2.24 M | 2.24 M | 745 K | 745 K | 745 K | 745 K | 935 K | 935 K | 935 K | 935 K |
Accounts Receivables |
2.67 M | 2.63 M | 252 K | 118 K | 1.31 M | 347 K | 189 K | 97 K | 243 K | 172 K | 197 K | 496 K | 1.83 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.02 M | 1.02 M | 1.02 M | 1.02 M | 3.16 M | 3.16 M | 3.16 M | 3.16 M | 1.88 M | 1.88 M | 1.88 M | 1.88 M | 1.78 M | 1.78 M | 1.78 M | 1.78 M | 970 K | 970 K | 970 K | 970 K | 427 K | 427 K | 427 K | 427 K | 489 K | 489 K | 489 K | 489 K | 44 K | 44 K | 44 K | 44 K | 170 K | 170 K | 170 K | 170 K |
Total Inventories |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency